12 Participants Needed

Deep Brain Stimulation Surgery for Treatment Resistant Depression

Recruiting at 1 trial location
HE
NP
RE
NI
Overseen ByNadia Imran
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of California, Los Angeles
Must be taking: Antidepressants
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial requires that you stay on your current antidepressant medication throughout the study, unless there are safety concerns.

What data supports the effectiveness of this treatment for treatment-resistant depression?

Research shows that deep brain stimulation (DBS) can help people with treatment-resistant depression, with about 50% of patients responding well to it. Some studies even suggest that targeting specific brain areas might improve response rates to over 70%.12345

Is deep brain stimulation generally safe for humans?

Deep brain stimulation (DBS) has been used in various conditions like Parkinson's disease and treatment-resistant depression. While it can reduce symptoms, there are potential complications such as hardware failure and surgery-related issues. Safety data is limited, but some studies report complications related to the device and surgical procedure.16789

How is the Abbott Laboratories Infinity DBS System treatment different from other treatments for treatment-resistant depression?

The Abbott Laboratories Infinity DBS System is unique because it involves deep brain stimulation (DBS), a surgical procedure that uses electrical impulses to regulate brain circuits involved in depression. Unlike medications, DBS is adjustable and reversible, offering a novel approach for patients who do not respond to traditional treatments.23101112

What is the purpose of this trial?

Treatment resistant depression remains a major problem for individuals and society. Surgical procedures may provide relief for some of these patients. The most frequently considered surgical approach is deep brain stimulation (DBS) of a part of the brain called the subcallosal cingulate region. However, the effectiveness and safety is not well established. The investigators will use a novel approach using advanced imaging technique (magnetic resonance tractography) to evaluate the feasibility and safety of this surgical approach. An innovative method for the definition of DBS target will be applied that redefines the concept of targeting as one of targeting a symptomatic network rather than a structural brain region using subject-based brain anatomy to define the target location. The correlation between imaging findings at baseline with the mood score changes at different time points of the study will be investigated.

Research Team

NP

Nader Pouratian

Principal Investigator

UT Southwestern Medical Center

Eligibility Criteria

This trial is for adults aged 21-70 with treatment-resistant depression, defined as not responding to at least four different types of antidepressant treatments. Participants must have a current major depressive episode lasting over 24 months or recurrent illness, and severe symptoms measured by specific scales. They should be on stable medication for at least one month before the study and able to attend regular clinic visits for a year.

Inclusion Criteria

I am between 21 and 70 years old and not pregnant.
I will keep taking my current antidepressant unless it's unsafe.
My cognitive function is good, with a MoCA score above 25.
See 14 more

Exclusion Criteria

I don't have any health conditions that would make surgery risky for me.
I have had a bleeding stroke in the past.
You should not have diathermy treatment during the study.
See 14 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Open-label Period

Participants receive open-label DBS to optimize stimulation settings

8 weeks

Randomized Discontinuation Period

Participants are randomized to either 'OFF then ON' or 'ON then OFF' DBS for 8 weeks each

16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

18 months

Treatment Details

Interventions

  • Abbott Laboratories Infinity™ implantable deep brain stimulation system
Trial Overview The trial tests the Abbott Laboratories Infinity™ deep brain stimulation system targeting the subcallosal cingulate region in the brain using magnetic resonance tractography. This novel approach aims to redefine DBS target based on individual brain anatomy and symptomatic networks rather than structural regions.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Randomized Discontinuation Period: ON then OFF DBSExperimental Treatment1 Intervention
Subjects randomized to this arm are initially "ON" DBS with optimized stimulation settings for 8 weeks after the open label period and then "OFF" DBS with gradually decreasing amplitude for 8 weeks.
Group II: Randomized Discontinuation Period: OFF then ON DBSExperimental Treatment1 Intervention
Subjects randomized to this arm are initially "OFF" DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then "ON" DBS for 8 weeks.

Abbott Laboratories Infinity™ implantable deep brain stimulation system is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Infinity DBS System for:
  • Essential tremor
  • Parkinson's disease
  • Dystonia
  • Obsessive-compulsive disorder
  • Epilepsy
🇪🇺
Approved in European Union as Infinity DBS System for:
  • Essential tremor
  • Parkinson's disease
  • Dystonia
  • Obsessive-compulsive disorder
  • Epilepsy
🇨🇦
Approved in Canada as Infinity DBS System for:
  • Essential tremor
  • Parkinson's disease
  • Dystonia
  • Obsessive-compulsive disorder
  • Epilepsy

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Los Angeles

Lead Sponsor

Trials
1,594
Recruited
10,430,000+

Nader Pouratian

Lead Sponsor

Trials
4
Recruited
20+

Findings from Research

Deep brain stimulation (DBS) has shown promising results in treating therapy-refractory major depressive disorder (MDD), with studies indicating significant reductions in depression scores: 36% for nucleus accumbens, 44% for internal capsule/ventral striatum, and 52% for subcallosal cingulate gyrus after one year.
The side effects of DBS have been minor, and a notable percentage of patients achieved remission, with 30% in the nucleus accumbens group and 40% in the internal capsule/ventral striatum group, suggesting that DBS could be a viable option for patients who do not respond to traditional treatments.
Deep brain stimulation in the treatment of depression.Blomstedt, P., Sjöberg, RL., Hansson, M., et al.[2010]
Deep brain stimulation (DBS) targeting the subcallosal cingulate cortex (SCC) shows promising efficacy for treatment-resistant depression (TRD), with response rates ranging from 23% to 92% and remission rates between 27% and 66.7% based on a review of 14 studies involving 230 patients.
The adverse effects associated with SCC DBS are generally transient and related to stimulation, indicating a favorable safety profile for this experimental treatment in TRD.
Subcallosal Cingulate Cortex Deep Brain Stimulation for Treatment-Resistant Depression: A Systematic Review.Sobstyl, M., Kupryjaniuk, A., Prokopienko, M., et al.[2022]
Deep brain stimulation (DBS) has shown a significant increase in response rates and reduction in depressive symptoms compared to sham treatment, based on a meta-analysis of 190 participants from nine studies.
Despite its promise for treatment-resistant depression, DBS is still considered experimental due to potential publication bias and the occurrence of serious adverse effects in some patients, indicating the need for further research.
A systematic review and meta-analysis of deep brain stimulation for depression.Kisely, S., Li, A., Warren, N., et al.[2019]

References

Deep brain stimulation in the treatment of depression. [2010]
Subcallosal Cingulate Cortex Deep Brain Stimulation for Treatment-Resistant Depression: A Systematic Review. [2022]
A systematic review and meta-analysis of deep brain stimulation for depression. [2019]
Detailed Anatomical Volumetric Study of Deep Nuclei of Brain and Other Structures Between Parkinson's Disease Patients Who Had Deep Brain Stimulation and Control Group. [2022]
Distance to white matter trajectories is associated with treatment response to internal capsule deep brain stimulation in treatment-refractory depression. [2021]
Complications of deep brain stimulation in Parkinson's disease: a single-center experience of 517 consecutive cases. [2023]
Long-term deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression. [2020]
Placement of the Internal Pulse Generator for Deep Brain Stimulation in the Upper Back to Prevent Fracture of the Extension Wire due to Generator Rotation: Case Report. [2021]
Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery--experiences from a single centre. [2022]
[The Value of Deep Brain Stimulation in Difficult-To-Treat and Treatment-Refractory Depression]. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
Deep brain stimulation for treatment-resistant depression: systematic review of clinical outcomes. [2021]
12.United Statespubmed.ncbi.nlm.nih.gov
Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security